

Date: 11th July 2022

To, Listing Compliance Department, National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai-400051

NSE Symbol: Madhavbaug

Subject: Agreement to acquire Equity shares of Cure and Care Primary Care Private Limited {Raphacure}

Dear Sir/Madam,

With reference to the captioned subject, we would like to inform you that the Company along with Promoter, Dr. Rohit Madhav Sane has executed a shareholding agreement with Cure and Care Primary Care Private Limited widely known as {hereinafter referred as Raphacure} on 11th July 2022 where a company and Promoter shall be entitle to hold 17.5% and 2% of total share capital of post issue of equity shares on preferential basis.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09th September 2015 are as under:

Sr. No.	Particulars	Disclosures
1.	Name of the target entity, details in brief such as Size, turnover etc.	Name: Cure and Care Primary Care Private Limited Paid Up Capital: Rs. 4,72,000/- Turnover: Rs. 82.24 Lakhs Estimated{FY 2021-22 was a First Financial Year for
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the	Raphacure} Currently, There is no related party Transaction, however, shares to the tune upto 2% will also be acquired by Dr. Rohit Madhav Sane, MD & CEO and Promoter, then it will fall into Related Party Transaction. Transaction will fall at "Arm's Length
	same is done at "Arm's Length"	Basis"

VAIDYA SANE AYURVED LABORATORIES LIMITED

2	To decate 1 111	
3.	Industry to which the entity being acquired belongs	Healthcare and Technology
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Our engagement with RaphaCure signifies our commitment to leveraging technology for providing better patient care to our patient, this will bring innovative healthcare to patient's doorsteps, which will result in a collaborative growth for both companies
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None
6.	Indicative time period for completion of the acquisition	Approx. 3 months
7.	Nature of consideration -whether cash consideration or share swap and details of the same	Cash Transaction
8.	Cost of acquisition or the price at which the shares are acquired	Equity shares will be allotted to the Company and Promoter at Face Value of Rs. 10 Each
9.	Percentage of shareholding / control	Madhavbaug- 10,261 Equity Shares of Rs. 10 Each constituting 17.50% of Share Capital Dr. Rohit Sane- 1,173 Equity Shares of Rs. 10 Each constituting 2.00% of Share capital
10.	Brief Background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	RaphaCure is a leading healthcare management company that leverages cutting-edge technology applications to provide a host of services including telemedicine, diagnostic tests, COVID care, and wellness solutions to individual patients and corporate houses. Headquartered in Bangalore, the company has tie-ups with more than 1,500 hospitals across India.
		With collaboration with Raphacure, Madhavbaug envisages to bring innovative healthcare services including pathology and investigation services at its patient's doorsteps where it allows patients to give various pathology tests at

their house.
Raphacure is incorporated on 22 nd April 2021, there is audited turnover is available as of now.

Kindly take this on your record.

For, Vaidya Sane Ayurved Laboratories Limited

Abhishek Deshpande

Company Secretary & Compliance Officer